OvaScience, Inc. (NASDAQ:OVAS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

OvaScience, Inc. (NASDAQ:OVAS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 5, 2017, the Compensation Committee of the Board of Directors of OvaScience, Inc. (the “Company”) approved a retention plan (the “Retention Plan”) providing for cash bonuses and equity grants for employees of the Company, including its Chief Financial Officer, Christophe Couturier. The purpose of the Retention Plan is to incentivize employees to remain with the Company following the recently announced corporate restructuring. to the Retention Plan, participating employees will receive equity grants that vest over a two year period and cash bonuses, payable either in a lump sum or over time, subject to the employees’ remaining with the Company as of the vesting or payment dates. Mr. Couturier will receive an option to purchase 100,000 shares of the Company’s common stock, $0.01 par value per share, vesting in equal quarterly amounts over two years, and a cash bonus totaling $100,000, payable in two tranches of $50,000 each in the first pay periods following June 30, 2017 and December 31, 2017, subject to his remaining with the Company on such dates.



About OvaScience, Inc. (NASDAQ:OVAS)

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.

OvaScience, Inc. (NASDAQ:OVAS) Recent Trading Information

OvaScience, Inc. (NASDAQ:OVAS) closed its last trading session up +0.01 at 1.69 with 426,010 shares trading hands.